Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.

NCT07627568 · tracked via the Priya Life Science Germany tracker

Sponsor

University of Freiburg

Phase

Observational

Started

2026-05-30

Last updated

2026-06-10

Condition(s) studied

Acute Myeloid Leukemia

Study summary

The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Diagnosis of acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements * Hematological relapse after allo-HCT * 18 years or older Exclusion Criteria: * no signed informed consent

Primary outcome measure(s)

Correlative biomarker — 1 year
HERV expression by AML cells
Biomarkers will be correlated with survival and leukemia response — may 2026 till may 2027
The biomarkers HERV, HLA class I and II, T cell phenotype

Trial sites (1)

Facility	City	Region	Status
University of Freiburg Mdical Center	Freiburg im Breisgau	Germany	Recruiting

More University of Freiburg trials in Germany

Spinal CSF Leaks in Chronic Subdural Hematoma Recruiting

Combination of Hypothermia and Thrombectomy in Acute Stroke Recruiting

Investigation of a New Window Into Intracranial Pressure: Venous Occlusion Pressure of the Isolated Periorbital Vein Recruiting

Other trials for the same condition

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia Active, not recruiting

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) Enrolling by invitation

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 Active, not recruiting

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation Recruiting

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07627568 on ClinicalTrials.gov ↗ ← All trials in Germany